Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emtricitabine/Tenofovir, Colchicine, and Rosuvastatin for COVID-19 in Colombia
NCT04359095Phase 3Completed
- Sponsor
- Universidad Nacional de Colombia
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine, tenofovir, colchicine and rosuvastatin in coronavirus disease 2019 (COVID-19), sponsored by Universidad Nacional de Colombia. Started Aug 2020; status: completed.
02
Drugs
emtricitabinetenofovircolchicinerosuvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04359095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04359095.